Reviewing ClearPoint Neuro (NASDAQ:CLPT) and IceCure Medical (NASDAQ:ICCM)

ClearPoint Neuro (NASDAQ:CLPT) and IceCure Medical (NASDAQ:ICCM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, analyst recommendations and risk.

Insider and Institutional Ownership

30.1% of ClearPoint Neuro shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 6.9% of ClearPoint Neuro shares are held by company insiders. Comparatively, 2.4% of IceCure Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

ClearPoint Neuro has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.

Profitability

This table compares ClearPoint Neuro and IceCure Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-81.76%	-188.09%	-40.88%
IceCure Medical	-427.67%	-174.26%	-112.58%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for ClearPoint Neuro and IceCure Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1	0	2	0	2.33
IceCure Medical	2	0	3	0	2.20

ClearPoint Neuro presently has a consensus target price of $25.67, indicating a potential upside of 90.69%. IceCure Medical has a consensus target price of $52.50, indicating a potential upside of 2,411.96%. Given IceCure Medical’s higher probable upside, analysts plainly believe IceCure Medical is more favorable than ClearPoint Neuro.

Valuation and Earnings

This table compares ClearPoint Neuro and IceCure Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97 million	11.10	-$25.54 million	($1.18)	-11.41
IceCure Medical	$3.38 million	2.12	-$15.06 million	($8.52)	-0.25

IceCure Medical has lower revenue, but higher earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Summary

ClearPoint Neuro beats IceCure Medical on 9 of the 14 factors compared between the two stocks.

About ClearPoint Neuro

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.